Meta-analysis of alpha receptor antagonist for benign prostatic hyperplasia from papers that were published in Korea

Korean Journal of Urology

Volumn 46, Issue 3, 2005, Pages 252-258

  Chung, Byung Ha ^a   Yang, Kwang Mo ^a   Hong, Sung Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adrenergic alpha antagonists; Benign prostatic hyperplasia; Meta analysis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; KOREA; MALE; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; RELIABILITY; SCORING SYSTEM; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; URINE FLOW RATE;

EID: 19144373474     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ishizuka, O, Nishizawa O, Hirao Y, Ohshima S. Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. Int J Urol 2002;9:607-12
2. Lee JJ, Hong SJ. The effect of prazosin as a first-line therapy for the symptomatic benign prostatic hypertrophy. Korean J Urol 1993;34:855-9
3. Minn YG, Sung DW, Choi HP, Hong SJ, Lee MS. Effect of terazosin in symptomatic benign prostatic hyperplasia. Korean J Androl 1993;11:23-7
4. Kim HJ, Lee KS. Preliminary results of terazosin in the treatment of benign prostatic hypertrophy. Korean J Urol 1994;35: 750-4
5. Jeon JS, Song JM. A 24 week, double-blind, placebo-controlled study using terazosin in treatment of benign prostatic hyperplasia. Korean J Urol 1994;35:755-9
6. Lee SE, Son HC, Lee JH, Kim HH, Lee CW. The efficacy of terazosin in the treatment of benign prostatic hyperplasia: a randomized, placebo-controlled double blind study. Korean J Urol 1995;36:406-16
7. Jeong DH, Park YI. Clinical experience of symptomatic management of BPH with terazosin, doxazosin or combination of terazosin and finasteride. Korean J Urol 1998;39:772-6
8. Lee ES, Lee CW. Effect of tamsulosin, a selective α1A-adrenoreceptor antagonist, in benign prostatic hyperplasia. Korean J Urol 1998;38:158-66
9. Chung BH, Chung HJ, Hong SJ, Lee MS. Doxazosin in the symptomatic treatment of benign prostatic hyperplasia. Korean J Urol 1999;40:607-12
10. Chung BH, Chung HJ, Hong SJ. Long-term efficacy and safety of terazosin in the symptomatic treatment of benign prostatic hyperplasia. Korean J Androl 1999;17:45-50
11. Kim YD, Lee JG. The proper patient selection for the effective response of doxazosin in the management of benign prostatic hyperplasia. Korean J Urol 2001;42:65-8
12. de Mey C. α1-blockers for BPH: Are there differences? Eur Urol 1999;36(Suppl 3):52-63
13. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 1999;36:609-20
14. Fawzy A, Hendry A, Cook E, Gonzalez F. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. Int J Urol 1999;6:346-54
15. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 2002;167:1734-9
16. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98